In a recent report [39], DNA methylation and transcriptomic analysis showed a lower incidence in cGBMs compared with pGBMs and aGBMs of typical GBM-related copy number aberrations (CNAs) but identified cyclin dependent kinase 6 (CDK6) and cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletions and MET proto-oncogene, a receptor tyrosine kinase (MET) fusion gene. The gene discussed is CDK6; the disease is glioblastoma.